Overview Financials News + Filings Key Docs Ownership Insiders
|
|
Inhibikase Therapeutics, Inc.
|
|
| Common Size Income Statement |
|
|
|
|
Annual | Quarterly | TTM |
|
| In millions, except per share items | Jun-30-23 | Mar-31-23 | Dec-31-22 | Sep-30-22 | Jun-30-22 | Mar-31-22 | Dec-31-21 | Sep-30-21 |
| | 10-Q | 10-Q | 10-K | 10-Q | 10-Q | 10-Q | 10-K | 10-Q |
| Revenues | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% |
| Cost of goods sold | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 229.5% | 258.8% | 287.4% |
| Gross profit | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | -129.5% | -158.8% | -187.4% |
| Selling, general and administrative | 2617.9% | 4560.5% | | 10556.5% | 1731.7% | 285.6% | | 8.4% |
| Research and development | 5332.1% | 8364.8% | 9749.7% | 20012.1% | 3275.3% | 549.7% | 211.1% | 96.5% |
| General and administrative | | | 1089.1% | | | | 53.3% | |
| Depreciation | 65.2% | 3.6% | 0.0% | 2.7% | | | | |
| EBIT | -7850.0% | -12825.3% | -14686.2% | -30468.6% | -4907.0% | -951.4% | -461.5% | -292.1% |
| Pre-tax income | -7557.7% | -12605.7% | -14625.9% | -30438.9% | -4907.1% | -965.2% | -476.9% | -335.0% |
| Income taxes | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Net income | -7557.7% | -12605.7% | -14625.9% | -30438.9% | -4907.1% | -965.2% | -476.9% | -335.0% |
|